华熙生物：国寿成达阶段性减持落地，控股股东逆势增持托底信心

Core Viewpoint - The orderly exit of institutional shareholders and the continuous increase in holdings by the controlling shareholder create a positive balance, optimizing the company's equity structure and enhancing market liquidity and capital stability, which is favorable for long-term investors [2] Group 1: Shareholder Actions - Guoshou Chengda plans to reduce its stake in Huaxi Biological by up to 2% of the total share capital between November 24, 2025, and February 20, 2026, as part of a normal exit within the fund's investment cycle [1] - After the reduction, Guoshou Chengda's shareholding will fall below 5%, no longer constituting a related party relationship, potentially allowing insurance and asset management funds to reinvest in Huaxi Biological [1] - The controlling shareholder, Huaxi Xinyu Investment Co., completed an increase in holdings by acquiring approximately 4.519 million shares for about 257 million yuan, raising its stake to 60.11% [1] Group 2: Business Strategy and Market Position - Huaxi Biological focuses on synthetic biology manufacturing, establishing an integrated business layout in the field of aging intervention, providing comprehensive solutions across pharmaceuticals, medical aesthetics, nutritional science, and dermatology [2] - The company is one of the few globally that has a comprehensive layout in the ECM (extracellular matrix) field, with a core research direction centered on the overall synergy of ECM key substances [2] - Huaxi Biological's growth stems from its ability to integrate various scientific dimensions, forming a complete layout in life-active substances, medical aesthetics, functional skincare, and oral nutrition [3] Group 3: Innovation and Development - The company exemplifies the transition of Chinese manufacturing enterprises towards foundational research and brand transformation, leveraging technological innovation to drive industry iteration [4] - Huaxi Biological has become a global leader in hyaluronic acid production, transitioning from animal extraction to microbial fermentation, significantly reducing costs while improving quality and stability [4] - The profits generated are reinvested into foundational and applied research, opening doors to cell biology and glycoscience, and positioning the company for success in technological innovation and brand building [4]